Biotech Stocks Are Soaring In Pre-Market Update at Mid Morning
NASDAQ Up 39 to 5031 Healthcare Stocks Continue To Lead
Biogen Idec (BIIB) Up 10% On Alzheimer Disease Phase 1 Data
Encouraging Phase I data on aducanumab with 166 patients shows acceptable safety and amyloid plaque reduction prompts Company to skip early stage study and move on to Phase 3.
Update at Mid-morning